Long-term management of HIV/hepatitis C virus associated psoriasis with etanercept

[3] Etanercept or other TNF-α inhibitors have been administered effectively in patients with plaque or pustular psoriasis or psoriatic arthritis refractory to conventional treatments in the setting of HIV infection. [6] Etanercept has no activity on p55 receptor, and therefore may have some theoretic advantage in minimizing the potential risk of toxoplasmosis. Since the conceivable risk of opportunistic infections, a firm alliance between dermatologists and infectious diseases specialists remains mandatory in the managing of psoriatic patients with HIV/HCV co-infection.